Gabelli Securities Lowered Moneygram International Co (MGI) Holding By $2.30 Million; Alkermes PLC Has 1.04 Sentiment

February 21, 2018 - By Winifred Garcia

Gabelli Securities Inc decreased Moneygram International Inc Co (MGI) stake by 49.43% reported in 2017Q3 SEC filing. Gabelli Securities Inc sold 143,789 shares as Moneygram International Inc Co (MGI)’s stock rose 32.68%. The Gabelli Securities Inc holds 147,102 shares with $2.37M value, down from 290,891 last quarter. Moneygram International Inc Co now has $626.49 million valuation. The stock increased 1.50% or $0.17 during the last trading session, reaching $11.54. About 22,202 shares traded. MoneyGram International, Inc. (NASDAQ:MGI) has risen 183.58% since February 21, 2017 and is uptrending. It has outperformed by 166.88% the S&P500.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $10.12 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Analysts await MoneyGram International, Inc. (NASDAQ:MGI) to report earnings on March, 21. They expect $0.19 EPS, up 18.75% or $0.03 from last year’s $0.16 per share. MGI’s profit will be $10.31M for 15.18 P/E if the $0.19 EPS becomes a reality. After $0.21 actual EPS reported by MoneyGram International, Inc. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.

Investors sentiment decreased to 0.81 in Q3 2017. Its down 0.56, from 1.37 in 2017Q2. It turned negative, as 21 investors sold MGI shares while 31 reduced holdings. 16 funds opened positions while 26 raised stakes. 46.30 million shares or 3.00% less from 47.73 million shares in 2017Q2 were reported. Northern Corp has invested 0% in MoneyGram International, Inc. (NASDAQ:MGI). Blackrock reported 0% in MoneyGram International, Inc. (NASDAQ:MGI). Great West Life Assurance Can reported 0% in MoneyGram International, Inc. (NASDAQ:MGI). Balyasny Asset Mngmt Limited Company holds 0% in MoneyGram International, Inc. (NASDAQ:MGI) or 69,752 shares. Quantbot Techs Limited Partnership has 0.04% invested in MoneyGram International, Inc. (NASDAQ:MGI) for 25,076 shares. Gamco Investors Et Al reported 64,434 shares or 0.01% of all its holdings. Victory Capital Mngmt Incorporated owns 9,011 shares or 0% of their US portfolio. Wellington Gru Llp reported 275,619 shares or 0% of all its holdings. Pacad invested 0.03% of its portfolio in MoneyGram International, Inc. (NASDAQ:MGI). Amer Intll Group has 0% invested in MoneyGram International, Inc. (NASDAQ:MGI). California State Teachers Retirement Sys reported 0% in MoneyGram International, Inc. (NASDAQ:MGI). Alliancebernstein LP owns 29,800 shares. Royal Bancshares Of Canada has 0% invested in MoneyGram International, Inc. (NASDAQ:MGI) for 2,874 shares. Dimensional Fund Advsrs Limited Partnership reported 0.01% of its portfolio in MoneyGram International, Inc. (NASDAQ:MGI). 140,000 were reported by Polar Asset Mgmt Prns.

Among 8 analysts covering Moneygram International (NASDAQ:MGI), 1 have Buy rating, 2 Sell and 5 Hold. Therefore 13% are positive. Moneygram International had 12 analyst reports since August 3, 2015 according to SRatingsIntel. On Monday, July 24 the stock rating was maintained by Northland Capital with “Hold”. The rating was downgraded by Feltl & Co to “Hold” on Monday, January 30. J.P. Morgan downgraded the shares of MGI in report on Tuesday, December 12 to “Sell” rating. On Thursday, January 26 the stock rating was downgraded by First Analysis to “Equal-Weight”. The firm earned “Hold” rating on Tuesday, July 18 by Northland Capital. The rating was upgraded by Evercore to “Sell” on Monday, August 3. The rating was maintained by Northland Capital on Wednesday, October 11 with “Hold”. The stock of MoneyGram International, Inc. (NASDAQ:MGI) earned “Neutral” rating by Compass Point on Monday, November 2. The stock of MoneyGram International, Inc. (NASDAQ:MGI) has “Hold” rating given on Thursday, June 29 by Northland Capital. The firm earned “Hold” rating on Tuesday, September 5 by Northland Capital.

Gabelli Securities Inc increased Cu Bancorp Calif Com (NASDAQ:CUNB) stake by 84,442 shares to 371,142 valued at $14.39M in 2017Q3. It also upped Grifols Sa Sp Adr Rep B Nvt (NASDAQ:GRFS) stake by 233,775 shares and now owns 263,175 shares. Dominion Diamond Corp Com (NYSE:DDC) was raised too.

Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 7.99% above today’s ($64.82) share price. ALKS was included in 3 notes of analysts from October 21, 2016. The stock of Alkermes plc (NASDAQ:ALKS) has “Outperform” rating given on Friday, October 21 by Leerink Swann. The stock of Alkermes plc (NASDAQ:ALKS) earned “Buy” rating by Jefferies on Friday, October 21. JP Morgan upgraded the shares of ALKS in report on Friday, October 21 to “Overweight” rating.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on April, 26. They expect $-0.22 earnings per share, up 29.03% or $0.09 from last year’s $-0.31 per share. After $0.20 actual earnings per share reported by Alkermes plc for the previous quarter, Wall Street now forecasts -210.00% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>